000			01970 a2200529 4500
005			20250515181027.0
264		0	_c20090929
008			200909s 0 0 eng d
022			_a1090-2430
024	7		_a10.1016/j.expneurol.2009.07.002 _2doi
040			_aNLM _beng _cNLM
100	1		_aPiltonen, Marjo
245	0	0	_aHeparin-binding determinants of GDNF reduce its tissue distribution but are beneficial for the protection of nigral dopaminergic neurons. _h[electronic resource]
260			_bExperimental neurology _cOct 2009
300			_a499-506 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAnimals
650	0	4	_aBehavior, Animal _xdrug effects
650	0	4	_aCarrier Proteins _xtherapeutic use
650	0	4	_aCytokines _xtherapeutic use
650	0	4	_aDisease Models, Animal
650	0	4	_aDopamine _xmetabolism
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aGlial Cell Line-Derived Neurotrophic Factor _xgenetics
650	0	4	_aMale
650	0	4	_aMitogen-Activated Protein Kinase Kinases _xmetabolism
650	0	4	_aMotor Activity _xdrug effects
650	0	4	_aNeurons _xdrug effects
650	0	4	_aOxidopamine
650	0	4	_aParkinson Disease, Secondary _xchemically induced
650	0	4	_aRats
650	0	4	_aRats, Wistar
650	0	4	_aSequence Deletion _xgenetics
650	0	4	_aStereotyped Behavior _xdrug effects
650	0	4	_aSubstantia Nigra _xpathology
650	0	4	_aTissue Distribution _xdrug effects
650	0	4	_aTyrosine 3-Monooxygenase _xmetabolism
700	1		_aBespalov, Maxim M
700	1		_aErvasti, Dagmar
700	1		_aMatilainen, Tero
700	1		_aSidorova, Yulia A
700	1		_aRauvala, Heikki
700	1		_aSaarma, Mart
700	1		_aMännistö, Pekka T
773	0		_tExperimental neurology _gvol. 219 _gno. 2 _gp. 499-506
856	4	0	_uhttps://doi.org/10.1016/j.expneurol.2009.07.002 _zAvailable from publisher's website
999			_c19024557 _d19024557